Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 3/20 | 0.68 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.59 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3677907 | 0.98 | SLC2A1 (0.68) | SLC2A1P2RY12P4HTMMAOBMALT1 | |
| SCHEMBL31107157 | 0.97 | SLC2A1 (0.67) | SLC2A1P2RY12P4HTMMAOBMALT1 | |
| SCHEMBL13930624 | 0.97 | SLC2A1 (0.67) | SLC2A1P2RY12P4HTMMAOBMALT1 | |
| SCHEMBL4258257 | 0.90 | SLC2A1 (0.67) | SLC2A1P2RY12P4HTMMAOBMALT1 | |
| SCHEMBL3683318 | 0.90 | SLC2A1 (0.65) | SLC2A1P2RY12P4HTMMAOBMALT1 | |
| SCHEMBL4252921 | 0.90 | SLC2A1 (0.67) | SLC2A1P2RY12P4HTMMAOBMALT1 | |
| SCHEMBL13930613 | 0.88 | SLC2A1 (0.62) | SLC2A1P2RY12P4HTMMAOBMALT1 | |
| SCHEMBL31107155 | 0.88 | SLC2A1 (0.62) | SLC2A1P2RY12P4HTMMAOBMALT1 | |
| 3-Chloroaniline SCHEMBL3676148 | 0.85 | SLC2A1 (0.61) | SLC2A1P2RY12P4HTMMAOBMALT1 | |
| SCHEMBL3676145 | 0.84 | SLC2A1 (0.60) | SLC2A1P2RY12P4HTMMAOBMALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2182935-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | claimed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | claimed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | claimed |
| US-20240307361-A1 | METHOD FOR DIAGNOSING AND TREATING IRRITABLE BOWEL SYNDROME | Centre for Chinese Herbal Medicine Drug Development Limited (CN) | 2024-09-19 | — | — | US | disclosed |
| US-20240295566-A1 | METHOD FOR DIAGNOSING AND TREATING METABOLIC DISORDERS | Centre for Chinese Herbal Medicine Drug Development Limited (CN) | 2024-09-05 | — | — | US | disclosed |
| EP-2182935-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307361-A1 | METHOD FOR DIAGNOSING AND TREATING IRRITABLE BOWEL SYNDROME | HRH4, VIPR1, TAAR1 | SLC2A1 1885/4885P2RY12 1169/4885P4HTM 2230/4885 |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | SLC2A1 2534/4885P2RY12 1299/4885P4HTM 2004/4885 |
| US-20240295566-A1 | METHOD FOR DIAGNOSING AND TREATING METABOLIC DISORDERS | TPH1, GPR119, TAAR1 | SLC2A1 130/4885P2RY12 1964/4885P4HTM 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.